Company profile
Pangea Bio | Inspired by nature, powered by AI
Developing transformative medicines for neurological disorders, deploying AI to uncover promising molecules from natural sources.
Updated 06 Jun 2026 16:52
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
SH01 | Transaction MzUwMDA3NzgyOWFkaXF6a2N4 | Paper/PDF filed
Published 29 Mar 2026 22:37
SH01 | Transaction MzUwMDA3OTg0N2FkaXF6a2N4 | Paper/PDF filed
Published 29 Mar 2026 22:37
Last accounts made up date
MA | Transaction MzQ0MjY3Nzc3OGFkaXF6a2N4 | Paper/PDF filed
Published 23 Nov 2024 11:09
RESOLUTIONS | Transaction WURGTUdKSzNhZGlxemtjeA | Paper/PDF filed
Published 22 Nov 2024 03:38
Company registered at Companies House
1 May 2024 to 30 Apr 2025
**Pangea Bio** is a **UK-based SME biotech**, advancing the field of drug discovery and development to address the high and growing unmet need in neurological and neurodegenerative diseases. Pangea is developing proprietary **small-molecule therapeutics with potential** to **prevent vision loss in open-angle glaucoma** (OAG), a disease with high unmet med...
